CRSP — CRISPR Therapeutics AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1674416 ·
Switzerland
Last close
$40.15
Market Cap
$3.89B
52W High
$63.45
52W Low
$39.79
ADV30
1,729,341
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 12,323,000 | -28,961,000 | -118,370,000 | -111,437,000 | 2,556,412,000 | 192,027,000 | 908,344,000 |
| Jun 2026 | 10,000,000 | -30,272,000 | -117,269,000 | -91,154,000 | 2,650,770,000 | 291,337,000 | 904,219,000 |
| Mar 2026 | 1,000,000 | -44,949,000 | -130,248,000 | -122,931,000 | 2,725,820,000 | 423,308,000 | 911,264,000 |
| Dec 2025 | 0 | -53,703,000 | -154,764,000 | -130,613,000 | 2,265,243,000 | 347,559,000 | 343,430,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-374,632,000
Investing CF
$-443,289,000
Financing CF
$719,956,000
CapEx
$-4,216,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.74
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,273,073,000
Inventory
—
Receivables
$0
ST Investments
$2,080,521,000
EBIT TTM
$-518,178,000
Pretax Income TTM
$-453,648,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$25,172,000
EBITDA
$-499,680,000
Free Cash Flow
$-215,401,248
Enterprise Value
$3,364,109,824
Total Cash
$2,272,548,096
Total Debt
$779,827,008
Shares Out
97,000,813
Trailing EPS
$-4.73
Book Value
$17.02
ROE
-25.6%
ROA
-13.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -664,571,000 | -581,599,000 | 2,265,243,000 | 343,430,000 | 1,921,813,000 | -345,014,000 |
| Dec 2024 | 35,000,000 | -466,566,000 | -366,252,000 | 2,242,034,000 | 309,954,000 | 1,932,080,000 | -142,774,000 |
| Dec 2023 | 370,000,000 | -222,538,000 | -153,610,000 | 2,229,571,000 | 346,768,000 | 1,882,803,000 | -260,375,000 |
| Dec 2022 | 436,000 | -673,161,000 | -650,175,000 | 2,243,057,000 | 367,578,000 | 1,875,479,000 | -495,741,000 |
TTM Snapshot
Revenues TTM
$13,392,000
NetIncome TTM
$-451,139,000
OpCashFlow TTM
—
Assets (Latest)
$2,650,770,000
Forward EPS
$-3.69
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $42.50 · spot: $40.19 · call volume: 791 · put volume: 104
Expected Move to 2027-04-16:
±$11.82
(29.41%) —
implied range
$28.37 –
$52.01
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.61B | $28.49 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
News headlines (Yahoo Finance, 1h cache)
Is CRISPR Therapeutics (CRSP) Undervalued As CTX310 Data Meets a Share Price Slide?
2026-11-18 11:09 · Yahoo
CRISPR Therapeutics (CRSP) Stock Could Be Above Fair Value On Its 50% Five Year Fall
2026-11-18 10:13 · Yahoo
CRISPR Therapeutics (CRSP) Flags Early CTX310 And Zugo Cel Wins In Two Big Markets
2026-11-18 09:10 · Yahoo
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2026-11-17 13:00 · Yahoo
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
2026-11-17 12:13 · Yahoo
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
2026-11-16 10:00 · Yahoo
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-11-10 13:30 · Yahoo
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scient
2026-11-09 14:16 · Yahoo
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
2026-11-08 15:30 · Yahoo
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
2026-11-06 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.